LINAGLIPTIN 5mg. IP

Belongs to a class of medications called dipeptidyl peptidase-4 [DPP-4] inhibitors that are primarily used in the management of type 2 diabetes. A potent antihyperglycaemic agent that shows highly selective, potent, dose-dependent inhibition of DPP-4, with ≥ 80% inhibition of DPP-4 throughout the 24-hour dosing interval. (Scott, 2011) An efficient and well-tolerated treatment choice for individuals with type 2 diabetes, including those experiencing renal impairment for whom other antihyperglycemic agents require a dosage adjustment or are not suitable. (Deeks, 2012) Significantly improves glucose control without causing weight gain or increasing the risk of hypoglycemia. (Fumiko Yamamoto, 2020) More efficacious than voglibose 0.2 mg in terms of improving glycaemic control in patients with type 2 diabetes. (Scott, 2011) Displays higher potency and long duration of DPP-4 inhibition compared to other DPP-4 inhibitors. (Manash P. Baruah, 2016) Slows the inactivation of the endogenous incretin hormones and reduces blood glucose levels. (Aronson, 2012) Provides significant decreases in hemoglobin A (1c) levels, along with reductions in fasting and post-meal blood sugar levels among individuals diagnosed with type 2 diabetes mellitus. (Neumiller, 2012) Produces a significant, clinically meaningful, and sustained improvement in glycaemic control along with improvements in β-cell function parameters. (S Del Prato, 2011) An efficacious, safe, and well-tolerated drug in patients with T2DM and various degrees of renal impairment. (Chu-qing Cao, 2015) A safe and effective treatment for patients unable to take metformin due to either renal impairment or intolerance. (Chu-qing Cao, 2015) A valuable treatment option for individuals diagnosed with type 2 diabetes irrespective of race or ethnic background. (Akiko Sarashina, 2016)